Top Line: Does thyroid remnant ablation improve recurrence free survival for differentiated thyroid cancer?
The Study: Post-operative radioactive iodine (RAI) can range from low dose remnant ablation to high dose treatment for suspected residual or metastatic disease. The rationale for remnant ablation is to eliminate any residual thyroid tissue in order to simplify laboratory and radiographic surveillance. The controversy is whether eliminating residual thyroid tissue actually reduces recurrence risk. Two large randomized trials have shown that lower dose radioactive iodine (30 mCi) results in similar success at thyroid remnant ablation and similar rates of recurrent when compared to higher dose RAI (100 mCi). IoN was a phase 3, non-inferiority trial in which 504 patients with differentiated thyroid cancer status post total thyroidectomy were randomized to receive low dose RAI (30 mCi) or not. The definition of “low risk” thyroid cancer is variable. IoN allowed patients with up to pT3 and N1a disease, however the majority (91%) had pT1-2 disease with <10% in each arm having T3 or N1 disease. Papillary carcinomas >4cm were allowed, but not follicular carcinomas >4cm. Those with angioinvasion, widely invasive, anaplastic, or poorly differentiated disease were not eligible. At 5 years, the rate of recurrence free survival was 96.9% with ablation and 97.9% without, which was deemed non-inferior. There were no thyroid cancer deaths during the follow up period. There was no significant difference in second primary cancers between groups. There were also no differences in toxicity. Not unexpected, recurrence was higher among those with T3 or N1 disease. Given the low proportion of T3 or N1 patients in the trial, the authors recommended caution in applying these results and omitting RAI ablation in these subsets.
TBL: Five year outcomes from the IoN trial show no reduction in recurrence when low dose RAI remnant ablation is performed for pT1-2 N0 differentiated thyroid cancer with no adverse features. | Mallick, Lancet 2025
The Study: Post-operative radioactive iodine (RAI) can range from low dose remnant ablation to high dose treatment for suspected residual or metastatic disease. The rationale for remnant ablation is to eliminate any residual thyroid tissue in order to simplify laboratory and radiographic surveillance. The controversy is whether eliminating residual thyroid tissue actually reduces recurrence risk. Two large randomized trials have shown that lower dose radioactive iodine (30 mCi) results in similar success at thyroid remnant ablation and similar rates of recurrent when compared to higher dose RAI (100 mCi). IoN was a phase 3, non-inferiority trial in which 504 patients with differentiated thyroid cancer status post total thyroidectomy were randomized to receive low dose RAI (30 mCi) or not. The definition of “low risk” thyroid cancer is variable. IoN allowed patients with up to pT3 and N1a disease, however the majority (91%) had pT1-2 disease with <10% in each arm having T3 or N1 disease. Papillary carcinomas >4cm were allowed, but not follicular carcinomas >4cm. Those with angioinvasion, widely invasive, anaplastic, or poorly differentiated disease were not eligible. At 5 years, the rate of recurrence free survival was 96.9% with ablation and 97.9% without, which was deemed non-inferior. There were no thyroid cancer deaths during the follow up period. There was no significant difference in second primary cancers between groups. There were also no differences in toxicity. Not unexpected, recurrence was higher among those with T3 or N1 disease. Given the low proportion of T3 or N1 patients in the trial, the authors recommended caution in applying these results and omitting RAI ablation in these subsets.
TBL: Five year outcomes from the IoN trial show no reduction in recurrence when low dose RAI remnant ablation is performed for pT1-2 N0 differentiated thyroid cancer with no adverse features. | Mallick, Lancet 2025

![[Thyroid]IoN](https://quadshotnews.com/wp-content/uploads/2025/06/685e0f0f8c658-768x512.png)